A 20 percent reduction in MACE over 39.8 months is the kind of outcome that changes clinical guidelines
This distinction is not a minor detail
The $149 monthly cost is substantially lower than emergency care for weight-related complications (diabetes, heart disease, joint damage), making semaglutide a cost-effective investment in long-term health prevention
References: [1] The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease [2] [3] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [4] STEP-HFpEF: Semaglutide Improves Symptoms, Physical Limitations, Weight Loss in Patients With HFpEF and Obesity
Luckily during a bone broth fast, you still obtain amino acids, such as glycine and proline, that help prevent the breakdown of valuable protein tissue found in muscles